ANNUAL REPORT AS PER REGULATION 34(1) OF LODR
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Asston Pharmaceuticals filed its 6th Annual Report and AGM Notice for FY 2024-25, which is its first annual report post-IPO listing on BSE in July 2025. The company reported total revenue of Rs. 2,561.02 lakhs, up 57.28% from Rs. 1,628.27 lakhs in the previous year. Profit before tax rose to Rs. 501.60 lakhs (from Rs. 325.01 lakhs), and profit after tax grew 58.47% to Rs. 385.28 lakhs (from Rs. 243.12 lakhs). Foreign exchange earnings stood at Rs. 2,157.68 lakhs, indicating strong export contribution. The company issued bonus shares (54.87 lakh shares) during the year and successfully completed an IPO oversubscribed 186 times. No dividend was declared, with the board opting to reinvest for growth.
Strong revenue and profit growth alongside a successful IPO signals robust business momentum and improved financial flexibility. The decision to skip dividends in favour of reinvestment and the significant bonus issue suggest management is prioritising expansion, which may appeal to growth-focused investors.